Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs

Abstract

Skin and soft tissue infections (SSTIs) are a common cause of hospital admission among elderly patients, and traditionally have been divided into complicated and uncomplicated SSTIs. In 2010, the FDA provided a new classification of these infections, and a new category of disease, named acute bacterial skin and skin structure infections (ABSSSIs), has been proposed as an independent clinical entity. ABSSSIs include three entities: cellulitis and erysipelas, wound infections, and major cutaneous abscesses This paper revises the epidemiology of SSTIs and ABSSSIs with regard to etiologies, diagnostic techniques, and clinical presentation in the hospital settings. Particular attention is owed to frail patients with multiple comorbidities and underlying significant disease states, hospitalized on internal medicine wards or residing in nursing homes, who appear to be at increased risk of infection due to multi-drug resistant pathogens and treatment failures. Management of ABSSSIs and SSTIs, including evaluation of the hemodynamic state, surgical intervention and treatment with appropriate antibiotic therapy are extensively discussed.

Development of Lipomer Nanoparticles for the Enhancement of Drug Release, Anti-Microbial Activity and Bioavailability of Delafloxacin

“…The pharmacokinetic parameters were calculated using WinNonlin software (Pharsight Co., Mountain View, CA, USA), and all values have been expressed as means ± standard deviation (SD). The noncompartmental pharmacokinetic model was used to calculate C max and the time to reach maximum concentration (T max ), AUC from 0 to t (AUC 0-24 ) and 0-inf (AUC 0-inf ), elimination rate constant (kz), half-life (T 1 2 ) and mean residence time (MRT).…”

“…Acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired pneumonia (CAP) are considered as the most common type of infection which require hospitalization, and are the leading cause of mortality and morbidity worldwide [1][2][3]. Delafloxacin (DFL) is a novel fourth-generation fluoroquinolone group of antibiotics approved for treatment in adults for ABSSSI and CAP [4,5].…”

Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

“…Given the increasing incidence of resistance to established antibiotic therapies, particularly in staphylococci, a need exists for an antibiotic with a novel mechanism of action that is safe and effective against drug-resistant ABSSSI pathogens and is available in both intravenous and oral formulations (5–10). …”

Simple and Accurate HPTLC-Densitometric Method for Quantification of Delafloxacin (A Novel Fluoroquinolone Antibiotic) in Plasma Samples: Application to Pharmacokinetic Study in Rats

“…Acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired respiratory tract infections (CARTIs) are the most common infections which require hospitalization of patients for the treatment [1,2]. Delafloxacin (DLX), which is a new fluoroquinolone antibiotic, recently approved for the treatment of both ABSSSIs and CARTIs by USFDA and for ABSSSIs only by EMA [3][4][5].…”